Each ml Patadin eye drops contains:
Active Substance: Olopatadine Hydrochloride USP equivalent to Olopatadine 1 mg.
Preservative: Benzalkonium Chloride 0.1 mg.
Patadin is a sterile ophthalmic solution containing Olopatadine Hydrochloride, a relatively selective H₁-receptor antagonist and mast cell stabilizer for topical administration to the eyes.
Clinical Pharmacology:
Olopatadine inhibits the release of histamine from the mast cell and is a relatively selective histamine H₁-antagonist that inhibits the in vivo and in vitro type 1 immediate hypersensitivity reaction including inhibition of histamine induced effects on human conjunctival epithelial cells. Olopatadine has no effects on alpha-adrenergic, dopamine and muscarinic type 1 and 2 receptors. Olopatadine was shown to have low systemic exposure after topical administration.
Patadin eye drops is indicated for the treatment of signs and symptoms (itchy, watery, red and swollen eyes and/or eyelids) of allergic conjunctivitis including vernal keratoconjunctivitis, vernal keratitis, blepharitis, blepharoconjunctivitis and giant papillary conjunctivitis.
The recommended dose of Patadin eye drops is 1 drop in the affected eye(s) two times daily.
*Prescription only*
Specific drug interaction studies have not been conducted with Olopatadine ophthalmic solution.
Overdose:
There is no information on Olopatadine overdose. However, excessive use of any medication can have serious consequences. If you suspect an overdose, seek medical attention without delay.
Olopatadine was found not to be teratogenic in rats and rabbits. There are, however, no adequate and well controlled studies in pregnant women. This drug should be used in pregnant women only if the potential benefit justifies the potential risk to the fetus.
It is not known whether topical ocular administration could result in sufficient systemic absorption to produce detectable quantities in the human breast milk. Nevertheless, caution should be exercised when Patadin is administered to a nursing mother.
Patients should be advised not to wear a contact lens if their eye is red. Olopatadine ophthalmic solution should not be used to treat contact lens related irritation. Benzalkonium Chloride, preservative of Patadin, may be absorbed by soft contact lenses. Patients who wear soft contact lenses and whose eyes are not red should be instructed to wait at least 10 minutes after instillation of Patadin eye drops before they insert their contact lenses. The treatment should be discontinued in the presence of an allergic reaction.
Store at below 30°C in a dry place protected from light. It is desirable that the contents should not be used more than one month after first opening of the bottle.